Research progress in neoadjuvant chemotherapy for locally advanced rectal cancer
Received:July 21, 2020  
View Full Text  View/Add Comment  Download reader
DOI:10.11915/j.issn.1671-5403.2021.07.115
Key words:rectal cancer  neoadjuvant chemotherapy  research progress This work was supported by Shanxi Province 136 Revitalization Medical Project
Author NameAffiliationE-mail
WANG Kang Department of General Surgery, Shanxi Bethune Hospital Affiliated to Shanxi Medical University, Taiyuan 030000,China ditv484qian@163.comresearch 
ZHANG Yue Department of Intensive Care Unit, Ninth Hospital of Xi′an, Xi′an 710054,China ditv484qian@163.comresearch 
HAN Zhen-Guo Department of General Surgery, Shanxi Bethune Hospital Affiliated to Shanxi Medical University, Taiyuan 030000,China ditv484qian@163.comresearch 
Hits: 174
Download times: 174
Abstract:
      The incidence and mortality of rectal cancer remain high in China. Standardized preoperative regimen of neoadjuvant chemoradiotherapy and total mesorectal excision has significantly reduced the risk of local recurrence of rectal cancer, but has not improved overall survival(OS). At present, radiotherapy has been shown to affect anal function, urination function, and sexual function. To minimize treatment-related toxicity and improve OS, reoperation with neoadjuvant chemotherapy without radiotherapy may be a better option. This review aimed to clarify the research status and feasibility of neoadjuvant chemotherapy in locally advanced rectal cancer.
Close